Overcoming the obstacles in the pharma/biotech industry: 2008 update.
In the face of patent expirations on blockbuster drugs and declining innovation in the industry, pharma/biotech companies are restructuring their research and development operations and are pursuing an aggressive strategy of acquisitions, licensing deals and research collaborations in an attempt to fill the gaps in their product pipelines.
Graul
Ann I
AI
ann.graul@thomsonreuters.com
Revel
Laura
L
Rosa
Esmeralda
E
Cruces
Elisabet
E
D001709:Biotechnology / Q000191:economics / Q000639:trends*; D017277:Drug Approval / Q000191:economics; D055808:Drug Discovery / Q000191:economics / Q000639:trends*; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D016568:Drugs, Generic / Q000191:economics; D006801:Humans; D010330:Patents as Topic; D012106:Research / Q000191:economics / Q000639:trends
D016568:Drugs, Generic